AMI Investment Management Inc. Has $3.48 Million Position in Johnson & Johnson (NYSE:JNJ)

AMI Investment Management Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 3.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,018 shares of the company’s stock after buying an additional 810 shares during the period. AMI Investment Management Inc.’s holdings in Johnson & Johnson were worth $3,483,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Chatham Capital Group Inc. raised its holdings in Johnson & Johnson by 0.6% during the 1st quarter. Chatham Capital Group Inc. now owns 51,194 shares of the company’s stock worth $8,098,000 after purchasing an additional 309 shares during the last quarter. Waterway Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $822,000. Strata Wealth Advisors LLC raised its stake in Johnson & Johnson by 219.2% during the first quarter. Strata Wealth Advisors LLC now owns 5,927 shares of the company’s stock worth $938,000 after buying an additional 4,070 shares during the last quarter. Sandy Cove Advisors LLC boosted its position in Johnson & Johnson by 4.4% during the first quarter. Sandy Cove Advisors LLC now owns 5,597 shares of the company’s stock valued at $885,000 after acquiring an additional 238 shares during the last quarter. Finally, Trilogy Capital Inc. grew its holdings in Johnson & Johnson by 91.5% during the 1st quarter. Trilogy Capital Inc. now owns 4,392 shares of the company’s stock worth $695,000 after acquiring an additional 2,099 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JNJ. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Monday, June 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $174.07.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $146.42 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a market cap of $352.39 billion, a PE ratio of 9.13, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52. The stock’s fifty day simple moving average is $148.14 and its two-hundred day simple moving average is $154.05. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.68 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.